Gadolinium-enhanced magnetic resonance imaging in temporal bone lesions.
A 2-year experience with an enhancement agent in magnetic resonance imaging (MRI) is examined through case presentations. Characteristics of the agent Gadolinium DTPA/Dimeglumin are reviewed. Radiographic capabilities in enhanced versus unenhanced MRI are compared. Temporal bone lesions, including acoustic neuromas and facial nerve neuromas, are presented. Recent experience with facial nerve enhancement in Bell's palsy is also presented. Greater accuracy in defining small temporal bone lesions and increased delineation of facial nerve involvement appear to be significant benefits with enhanced MRI.
Millen
S J
SJ
Department of Otolaryngology, Medical College of Wisconsin, Milwaukee.
Daniels
D L
DL
Meyer
G A
GA
D000328:Adult; D003287:Contrast Media; D003390:Cranial Nerve Neoplasms / Q000175:diagnosis*; D005154:Facial Nerve / Q000473:pathology; D005155:Facial Nerve Diseases / Q000175:diagnosis*; D005260:Female; D019786:Gadolinium DTPA; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008875:Middle Aged; D009442:Neurilemmoma / Q000175:diagnosis*; D009464:Neuroma, Acoustic / Q000175:diagnosis*; D009942:Organometallic Compounds; D004369:Pentetic Acid; D013701:Temporal Bone / Q000473:pathology*
D003287:Contrast Media; D009942:Organometallic Compounds; D004369:Pentetic Acid; D019786:Gadolinium DTPA